type I Gaucher disease
About
Gaucher disease is caused by mutations in the GBA gene that lead to a deficiency in glucocerebrosidase, which accumulates in macrophages. Type I is the most common type and does not involve the nervous system. Core dilemmas: ① Enzyme replacement therapy (ERT) requires lifelong intravenous infusion, which is extremely costly;② Bone lesions (osteonecrosis, fractures) seriously affect quality of life;③ Substrate reduction therapy (SRT) is an oral replacement, but long-term efficacy and safety remain to be observed.
Features & Symptoms
- GBA gene mutation
- Glucocerebrosidase deficiency
- hepatosplenomegaly, bone lesions
- anemia and thrombocytopenia
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Imiglucerase | Recombinant glucocerebrosidase, given intravenously every 2 weeks, is the standard enzyme replacement treatment for Gaucher disease. | FDA批准 | $200K - $400K/年 |
| Velaglucerase alfa | The recombinant enzyme produced by gene activation technology is equivalent to imiglucosidase. | FDA批准 | $200K - $400K/年 |
| Eliglustat | Glucoencephaloside synthesis inhibitor, oral substrate reduction therapy, suitable for suitable patients. | FDA批准 | $300K - $600K/年 |
Prognosis
ERT significantly improves prognosis and approaches normal life expectancy
Additional Notes
Notes: Treatment options: enzyme replacement therapy (ERT, imiglucinase or veranosidase alpha) and substrate reduction therapy (SRT, Eliglustat) can be selected and needs to be individualized according to the patient's condition; bone disease management: Bisphosphonates can improve bone mineral density, and analgesic drugs can be used for a short period of time when bone pain occurs; liver and spleen monitoring: Regular abdominal MRI is performed to monitor the size of the liver and spleen and diffuse infiltration; Bone infarction assessment: Bone infarction is an important complication of Gaucher's disease, requiring regular MRI examinations of the pelvis and lower limbs;Parkinson's disease risk: GBA mutation carriers are at increased risk of developing Parkinson's disease and require long-term monitoring. Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Prognosis: ERT can significantly improve prognosis and approach normal life expectancy.
Frequently Asked Questions
What is type I Gaucher disease?
Gaucher disease is caused by mutations in the GBA gene that lead to a deficiency in glucocerebrosidase, which accumulates in macrophages. Type I is the most common type and does not involve the nervous system. Core dilemmas: ① Enzyme replacement therapy (ERT) requires lifelong intravenous infusion, which is extremely costly;② Bone lesions (osteonecrosis, fractures) seriously affect quality of life;③ Substrate reduction therapy (SRT) is an oral replacement, but long-term efficacy and safety remain to be observed.
What are the symptoms of type I Gaucher disease?
GBA gene mutation,Glucocerebrosidase deficiency,hepatosplenomegaly, bone lesions,anemia and thrombocytopenia
How is type I Gaucher disease treated?
Imiglucerase: Recombinant glucocerebrosidase, given intravenously every 2 weeks, is the standard enzyme replacement treatment for Gaucher disease.; Velaglucerase alfa: The recombinant enzyme produced by gene activation technology is equivalent to imiglucosidase.; Eliglustat: Glucoencephaloside synthesis inhibitor, oral substrate reduction therapy, suitable for suitable patients.
What is the prognosis for type I Gaucher disease?
ERT significantly improves prognosis and approaches normal life expectancy